Merck's phase 3 KEYNOTE─B21 trial of Keytruda plus chemotherapy with or without radiotherapy to treat high─risk ...
Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-B21 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its …